Fibrogen Stock Fundamentals
| FGEN Stock | USD 0.42 0.03 7.69% |
FibroGen fundamentals help investors to digest information that contributes to FibroGen's financial success or failures. It also enables traders to predict the movement of FibroGen Stock. The fundamental analysis module provides a way to measure FibroGen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to FibroGen stock.
At this time, FibroGen's Interest Expense is very stable compared to the past year. As of the 29th of November 2024, Total Revenue is likely to grow to about 179.8 M, while Depreciation And Amortization is likely to drop about 7.2 M. FibroGen | Select Account or Indicator |
FibroGen Company Profit Margin Analysis
FibroGen's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current FibroGen Profit Margin | (0.97) % |
Most of FibroGen's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, FibroGen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
FibroGen Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, FibroGen has a Profit Margin of -0.9684%. This is 91.36% lower than that of the Biotechnology sector and 95.8% lower than that of the Health Care industry. The profit margin for all United States stocks is 23.75% lower than that of the firm.
FibroGen Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining FibroGen's current stock value. Our valuation model uses many indicators to compare FibroGen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across FibroGen competition to find correlations between indicators driving FibroGen's intrinsic value. More Info.FibroGen is rated # 4 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . At this time, FibroGen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the FibroGen's earnings, one of the primary drivers of an investment's value.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
FibroGen Fundamentals
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.97) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | (12.47 M) | ||||
| Shares Outstanding | 100.77 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 55.00 % | ||||
| Number Of Shares Shorted | 3.9 M | ||||
| Price To Earning | 97.67 X | ||||
| Price To Book | 53.83 X | ||||
| Price To Sales | 0.23 X | ||||
| Revenue | 147.75 M | ||||
| Gross Profit | (159.21 M) | ||||
| EBITDA | (261.4 M) | ||||
| Net Income | (284.23 M) | ||||
| Cash And Equivalents | 438.13 M | ||||
| Cash Per Share | 4.67 X | ||||
| Total Debt | 170.46 M | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 2.17 X | ||||
| Book Value Per Share | (2.07) X | ||||
| Cash Flow From Operations | (315.02 M) | ||||
| Short Ratio | 3.27 X | ||||
| Earnings Per Share | (1.23) X | ||||
| Target Price | 0.6 | ||||
| Number Of Employees | 486 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 39.2 M | ||||
| Total Asset | 423.53 M | ||||
| Retained Earnings | (1.84 B) | ||||
| Working Capital | 113.89 M | ||||
| Current Asset | 200.56 M | ||||
| Current Liabilities | 67.18 M | ||||
| Net Asset | 423.53 M |
About FibroGen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 12.7 M | 10 M | |
| Total Revenue | 147.8 M | 179.8 M | |
| Cost Of Revenue | 18.8 M | 17.9 M | |
| Stock Based Compensation To Revenue | 0.34 | 0.19 | |
| Sales General And Administrative To Revenue | 0.27 | 0.23 | |
| Research And Ddevelopement To Revenue | 1.91 | 1.06 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 1.52 | 2.88 | |
| Ebit Per Revenue | (1.91) | (1.81) |
Pair Trading with FibroGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.Moving against FibroGen Stock
| 0.62 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.55 | GANX | Gain Therapeutics | PairCorr |
| 0.51 | BHC | Bausch Health Companies | PairCorr |
| 0.48 | GILD | Gilead Sciences | PairCorr |
| 0.45 | EBS | Emergent Biosolutions | PairCorr |
The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.
The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out FibroGen Piotroski F Score and FibroGen Altman Z Score analysis. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (1.23) | Revenue Per Share 1.758 | Quarterly Revenue Growth 0.143 | Return On Assets (0.27) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.